Patents by Inventor Azra Pervin

Azra Pervin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND THERAPEUTICAL USE THEREOF
    Publication number: 20170050937
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: March 25, 2016
    Publication date: February 23, 2017
    Inventors: Sui Xiong Cai, Nilantha Sudath Sirisoma, Azra Pervin, John A. Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Patent number: 7618975
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: November 17, 2009
    Assignees: Myriad Pharmaceuticals, Inc., Cytovia, Inc.
    Inventors: Sui Xiong Cai, Nilantha Sudath Sirisoma, Azra Pervin, John A. Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman
  • COMPOUNDS AND THERAPEUTICAL USE THEREOF
    Publication number: 20080039479
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: July 23, 2007
    Publication date: February 14, 2008
    Applicants: Myriad Genetics, Incorporated, Cytovia, Inc.
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • COMPOUNDS AND THERAPEUTICAL USE THEREOF
    Publication number: 20080032974
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: July 17, 2007
    Publication date: February 7, 2008
    Applicants: Myriad Genetics, Incorporated, Cytovia, Inc.
    Inventors: Sui Xiong Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • COMPOUNDS AND THERAPEUTICAL USE THEREOF
    Publication number: 20070249601
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: March 29, 2007
    Publication date: October 25, 2007
    Applicants: Myriad Genetics, Incorporated, Cytovia, Inc.
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • COMPOUNDS AND THERAPEUTICAL USE THEREOF
    Publication number: 20070244113
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: March 1, 2007
    Publication date: October 18, 2007
    Applicants: Myriad Genetics, Incorporated, Cytovia, Inc
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • COMPOUNDS AND THERAPEUTICAL USE THEREOF
    Publication number: 20070244114
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: March 13, 2007
    Publication date: October 18, 2007
    Applicants: Myriad Genetics, Incorporated, Cytovia, Inc.
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • COMPOUNDS AND THERAPEUTICAL USE THEREOF
    Publication number: 20070208044
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: January 5, 2007
    Publication date: September 6, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Patent number: 7226927
    Abstract: The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: wherein A, Ar1, Ar2, R1 and R3 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: June 5, 2007
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A Drewe, P. Sanjeeva Reddy, Bao Nguyen, Azra Pervin
  • Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis
    Publication number: 20070043076
    Abstract: The present invention is directed to substituted 2-arylmethylene-N-aryl-N?-aryl-malonamides and analogs thereof. The present invention also relates to the discovery that the compounds are activators of caspases and inducers of apoptosis. Therefore, the activators os caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: October 5, 2004
    Publication date: February 22, 2007
    Inventors: Sui Cai, Azra Pervin, Shailaja Kasibhatla, Bao Nguyen
  • Compounds and therapeutical use thereof
    Publication number: 20050137213
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: July 6, 2004
    Publication date: June 23, 2005
    Applicant: Myriad Genetics, Incorporated
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Patent number: 6794400
    Abstract: The present invention is directed to optionally substituted 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs thereof, represented by the Formulae I and II: wherein A1, A2, Q and R1-R3 are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: September 21, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Bao Ngoc Nguyen, John Drewe, P. Sanjeeva Reddy, Shailaja Kasibhatla, Azra Pervin
  • Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Publication number: 20040097503
    Abstract: The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: 1
    Type: Application
    Filed: November 10, 2003
    Publication date: May 20, 2004
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, P. Sanjeeva Reddy, Bao Nguyen, Azra Pervin
  • Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
    Patent number: 6716851
    Abstract: The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: wherein A, Ar1, Ar2, R1 and R3 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: April 6, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, Bao Nguyen, Azra Pervin
  • Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
    Publication number: 20030069239
    Abstract: The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: 1
    Type: Application
    Filed: December 12, 2001
    Publication date: April 10, 2003
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, P. Sanjeeva Reddy, Bao Nguyen, Azra Pervin
  • 4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1- (arylcarbonyl) thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Publication number: 20030045581
    Abstract: The present invention is directed to optionally substituted 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs thereof, represented by the Formulae I and II: 1
    Type: Application
    Filed: June 3, 2002
    Publication date: March 6, 2003
    Inventors: Sui Xiong Cai, Bao Ngoc Nguyen, John Drewe, P. Sanjeeva Reddy, Shailaja Kasibhatla, Azra Pervin
  • Peptide nucleic acid precursors and methods of preparing same
    Patent number: 6433134
    Abstract: Novel and efficient syntheses create novel piperazinone intermediates which facilitate the production and use of PNAs. Such syntheses and the products enhance the feasibility of a system which permits the rapid identification of PNA oligomers useful as therapeutics, diagnostics and/or gene characterization tools. A first component of the system is a universal PNA library that most preferably incorporates one or more universal nucleotide bases into carefully selected positions within each oligomer species thereby providing the library with the screening ability of a much larger library. The second component of the system is a high throughput screening system that includes a number of assays designed to provide information on the binding activities of the different PNAs to a target nucleotide sequence (generally, a DNA or RNA sequence).
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: August 13, 2002
    Assignee: Biocept, Inc.
    Inventors: Andrew P. Patron, Azra Pervin